Sophie Agaugue
Marseille, 13009, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Butyrophilin 3A/2A1-independent activation of human Vγ9Vδ2 γδ T cells by bacteria.
Journal: PNAS nexus
Published: April 16, 2025
BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling.
Journal: Cell reports
Published: February 14, 2024
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
Journal: Science translational medicine
Published: October 20, 2021
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: March 24, 2021
Overcoming Target Driven Fratricide for T Cell Therapy.
Journal: Frontiers in immunology
Published: August 08, 2018
Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Journal: Future oncology (London, England)
Published: June 15, 2017
Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 04, 2015
Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.
Journal: European journal of immunology
Published: January 24, 2014
Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: January 24, 2014
HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment.
Journal: European journal of immunology
Published: June 09, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026